Recent Updates
Recently added Catalysts

ritonavir

Phase 3

HIV Infections | Small molecule | Infectious Disease |Abbott Laboratories|Last Updated: Feb 20, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

Clinical trial landscape

ritonavir · 2 trials · 2 indications

Phase 3 1Phase 2 1
NCT00038636A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase InhibitorsHIV Infections
COMPLETED36 Analytics
PHASE3COMPLETED
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
HIV InfectionsUnlock trial analytics

Study Endpoints

Primary Endpoints

Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Lopinavir/ritonavirDRUG -
RitonavirDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites7

Inclusion: * HIV positive * Are at least 18 years old * Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening * HIV RNA level \> 1000 copies/mL * Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcr...

Countries:United StatesFranceSpainAustralia
Unlock Eligibility Criteria